


AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I*:



wherein

R₁ is methyl;

R₂ is a residue of formula (c): -Y'-(CH₂)_n-(CF₂)_m-CH_pF_q (c),

wherein where

Y' is a direct bond, O, CO, CHOH or C=NOR₆, wherein R₆ is H, C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkynyl or benzyl;


n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2, 3, 4, 5 or 6, provided that the sum of n+m is 3-8;

each of p and q, independently, is 0, 1, 2 or 3, with the proviso that p + q = 3;

and the chain (CH₂)_n-(CF₂)_m-CH_pF_q contains at least two fluorine atoms and may, optionally, be interrupted by one carbon-carbon double or triple bond, one CO or one-to-three oxygen atoms;

R₃ is Z-X₂, wherein where Z is CH₂, CHF, CF₂ or CHMe, and X₂ is OH or a residue of formula (a):



wherein Z₁ is a direct bond, CH₂, CHF, CF₂ or O, and each of R₁₂ and R₁₃, independently, is H or C₁₋₄-alkyl, optionally substituted by 1, 2 or 3 halogen atoms; and

each of R₄ and R₅, independently, is H, C₁₋₄-alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl;

in free form or in salt form.

2. (Currently amended) A compound according to Claim 1, ~~wherein~~ where R_2 is selected from the group consisting of

- Y- C_nF_{2n+1} , wherein $n=3-8$, and Y is CH_2 , O or $C=O$;
- Y- $CH_2C_nF_{2n+1}$, wherein $n=1-7$, and Y is CH_2 , O or $C=O$;
- Y- $CH_2CH_2C_nF_{2n+1}$, wherein $n=1-6$, and Y is CH_2 , O or $C=O$;
- Y- $CH_2CH_2CH_2C_nF_{2n+1}$, wherein $n=1-5$, and Y is CH_2 , O or $C=O$;
- ~~-Y-(CH_2) $_n$ F, wherein $n=1-7$, and Y is CH_2 , O or $C=O$;~~
- Y-(CH_2) $_n$ CF₃, wherein $n=1-6$, and Y is CH_2 , O or $C=O$;
- Y-(CH_2) $_n$ CF₂CH₃, wherein $n=1-4$, and Y is CH_2 , O or $C=O$;
- Y-(CH_2) $_n$ (CF₂) $_m$ CHF₂, wherein $n=0-3$, $m=1-6$, $n+m = 3-7$, and Y is CH_2 , O or $C=O$; and
- Y-(CH_2) $_n$ C(O)CF₃, wherein $n=1-5$, and Y is CH_2 , O or $C=O$.

3-7. (Canceled)

8. (Previously presented) A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof in association with a pharmaceutically-acceptable diluent or carrier therefor.

9. (Previously presented) A pharmaceutical combination comprising a compound according to Claim 1, in free form or in pharmaceutically-acceptable salt form, and at least one co-agent selected from an immunosuppressant agent, an immunomodulatory agent, an anti-inflammatory agent and a chemotherapeutic drug.

10. (Previously presented) A method for treating disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases in a subject comprising administering to the subject in need thereof an effective amount of a compound

according to Claim 1, or a pharmaceutically-acceptable salt thereof.

11-19. (Canceled)

20. (New) The compound according to Claim 1 selected from the group consisting of:

(R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride;

(R)-2-amino-2-methyl-4-[4-(6,6,6-trifluoro-hexyloxy)-phenyl]-butan-1-ol hydrochloride;

1-[4-((R)-3-amino-4-hydroxy-3-methyl-butyl)-phenyl]-6,6,6-trifluoro-hexan-1-one; and

(R)-2-amino-2-methyl-4-[4-(7,7,7-trifluoro-heptyl)-phenyl]-butan-1-ol.